Orexo Advances on Addiction Drug Study Result: Stockholm Mover
This article is for subscribers only.
Orexo AB, a Swedish biotech company, rose to the highest level in five months in Stockholm trading after saying a study on its addiction medicine met expectations and was completed ahead of schedule.
The shares rose as much as 8.7 percent to 30 kronor, the highest price since Jan. 9. Orexo traded 7.6 percent higher at